{"id":"NCT05219968","sponsor":"Lyra Therapeutics","briefTitle":"Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults","officialTitle":"ENLIGHTEN 1: A Phase III, Randomized, Blinded, Controlled, Parallel-Group Trial to Evaluate the Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis (CRS) in Adults","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-01-27","primaryCompletion":"2024-03-04","completion":"2024-09-16","firstPosted":"2022-02-02","resultsPosted":"2025-05-02","lastUpdate":"2025-05-02"},"enrollment":196,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Sinusitis","Chronic Rhinosinusitis (Diagnosis)"],"interventions":[{"type":"DRUG","name":"LYR-210","otherNames":[]},{"type":"DRUG","name":"Sham procedure control","otherNames":[]},{"type":"OTHER","name":"Background Therapy","otherNames":[]}],"arms":[{"label":"LYR-210","type":"EXPERIMENTAL"},{"label":"Sham procedure control","type":"SHAM_COMPARATOR"}],"summary":"Multicenter, phase III, randomized, blinded, controlled, parallel group with safety extension phase with crossover or continued treatment.","primaryOutcome":{"measure":"Change From Baseline (CFBL) in the 7-day Average Composite Score of 3 Cardinal Symptoms (3CS) in Participants Without Nasal Polyps.","timeFrame":"24 Weeks","effectByArm":[{"arm":"LYR-210","deltaMin":-2.13,"sd":2.172},{"arm":"Sham Procedure Control","deltaMin":-2.06,"sd":2.136}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":22},"locations":{"siteCount":55,"countries":["United States","Austria","Czechia","Poland","Spain"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":124},"commonTop":["Epistaxis","Nasal Odour","Chronis Sinusitis","Sinusitis","Upper Respiratory Tract Infection"]}}